Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Siltuximab for Multiple Myeloma
Recruiting1 awardPhase 2
New York, New York
This trial is testing siltuximab, a medication that blocks a protein called IL-6, to help reduce severe symptoms like weakness and fatigue after a stem cell transplant. The target group is patients aged 60-75 with multiple myeloma or systemic amyloidosis. By reducing inflammation, the goal is to improve recovery and shorten hospital stays.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service